Almirall Expands in China with Shanghai Office to Boost Dermatology Innovation

Event summary

  • Almirall inaugurated new offices in Shanghai's Jing’an district on March 12, 2026, to foster innovation in medical dermatology through partnerships.
  • The company has invested over €1 billion in R&D for medical dermatology over the last decade, with 12.5% of 2025 net sales directed toward R&D.
  • Almirall's pipeline includes three ongoing proof-of-concept/Phase II studies, with additional programs expected to progress into Phase II/PoC studies within the next 12 months.
  • The collaboration with Simcere on the interleukin-2 mutant fusion protein (IL-2muFc) has advanced to Phase II clinical trials in China and the United States.

The big picture

Almirall's expansion into China aligns with the country's accelerating life sciences capabilities and licensing deals in the pharma sector. The move underscores the strategic importance of China as a hub for innovation and commercialization in medical dermatology. With a strong R&D focus and a growing pipeline, Almirall aims to leverage its expertise to benefit from China's expanding market for advanced dermatological treatments.

What we're watching

Partnership Success
Whether Almirall can replicate the success of its Simcere collaboration with new Chinese partners.
Regulatory Approvals
The pace at which Almirall's pipeline programs advance through clinical trials and gain regulatory approvals.
Market Penetration
How effectively Almirall can commercialize its existing products in China through local partnerships.